Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GLP-1 receptor agonists like tirzepatide are proving to be a meaningful tool against obesity-related obstructive sleep apnea (OSA), cutting breathing disruption events and driving significant weight loss. But they're not a full replacement for CPAP — they work best as a complement. New data also show these drugs can reduce cardiovascular risk in OSA patients and help predict who benefits most from treatment.
GLP-1 receptor agonists (GLP-1 RAs) — the class of drugs behind Ozempic and Zepbound — are emerging as a powerful adjunct in treating obstructive sleep apnea (OSA) tied to obesity. A review in JAMA Otolaryngology–Head & Neck Surgery found that GLP-1 RAs reduced apnea-hypopnea index (AHI) events by 5.7 to 21.9 per hour across six meta-analyses, with tirzepatide achieving 18–20% average weight loss and disease remission in 42–50% of patients in the SURMOUNT-OSA trials. The benefits are largely driven by reductions in tongue fat and parapharyngeal tissue — the culprits behind airway collapse.
That said, GLP-1 RAs aren't a silver bullet. CPAP still outperforms them on raw AHI reduction (~31 vs. ~22 events/hour), roughly 50% of tirzepatide-treated patients still have residual OSA, and weight tends to creep back when the drug is stopped. Experts recommend GLP-1 RAs as complementary therapy — especially for patients who can't tolerate CPAP or are preparing for upper airway surgery.
By the Numbers
Why it matters: With nearly 1 billion people globally living with OSA and obesity as a key driver, GLP-1 RAs offer clinicians a disease-modifying option that goes beyond symptom management — potentially reducing cardiovascular risk and expanding candidacy for other OSA interventions.
